Chicago – Modifications to a drug used for cancer patients may be beneficial for Alzheimer’s patients. As reported by Reuters, changes to the cancer drug Gleevec could aid in the development of new medications that help fight against the development of brain-damaging plaques associated with Alzheimer’s disease.
Nobel prize winning researcher Paul Greengard, who worked on the study, is quoted in the report as stating of the findings, “Our findings reveal that gamma-secretase activating protein is a potential target for a new class of anti-amyloid therapies.”
Greengard is further quoted as stating, “The development of compounds that work like Gleevec, but have the ability to pass the blood-brain barrier and target gamma-secretase activating protein could revolutionize the treatment of this disease.”
More information about the findings may be available in the Nature journal.
The latest in Cancer News
